TRANSFORM

TRANSFORM Alliance Members’ consensus positions in response the European Commission’s legislative proposals on the Pharmaceutical Package. These positions aim to drive positive change across the full lifecycle of ATMPs, hence they are listed according to their place in the lifecycle of a therapy, from research through to patient access, and must be viewed holistically.

On 13 October, the European Alliance for Transformative Therapies launched its MEP Charter with Solutions to Enable Safe and Timely Patient Access to Advanced Therapies in Europe, developed collaboratively with expert stakeholders. The Charter will serve as a guide for TRANSFORM’s action in the coming years, including for the MEPs to prepare the discussion of expected legislative files such as SoHO legislation, the General Pharmaceuticals legislations, the EHDS, among others.

The European Alliance for Transformative Therapies’ (TRANSFORM) Policy Asks advocate for a regulatory framework that enables safe and timely patient access to transformative therapies, building on the 2021 TRANSFORM Recommendations for Action. 

The European Alliance for Transformative Therapies’ (TRANSFORM) Policy Asks advocate for changes that offer potential solutions to unlock safe and timely patient access to authorised ATMPs in Europe, building on the 2021 TRANSFORM Recommendations for Action.

The TRANSFORM MEP Interest Group launched 5 Policy Asks on how to optimize cross-border patient access to transformative therapies at their online event on 10 November 2021.